3PBiovianManufacturingThe European CDMO Model, Powering Biologics InnovationEurope continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation. more ➔
Artificial IntelligenceRecap AI Circular Economy Conference 2026The AI Circular Economy Conference 2026, organised by nova-Institute, brought together 116 participants from 15 countries in Cologne and online to explore the transformation of the chemical and materials … more ➔
Life Sciences Innovations Made in EuropeResearch and Innovation as a Competitive Advantage – Legal framework for Life Sciences made in EuropeResearch and innovation are considered key resources for European competitiveness – and essential location factors for research-intensive industries such as the Life Sciences. The European Union is … more ➔
CDMO3PBIOVIAN and INC partner to expand access to oncology treatments in Colombia through biosimilar development3PBIOVIAN consolidates its position as a trusted partner for the development and manufacturing of complex biological products, combining scientific excellence, regulatory expertise, and strong social … more ➔
New England BiolabsThe Bridge to your successCustomized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product. more ➔
BioDlinkDrug developmentSolutions-Based Thinking: BioDlink’s Model for Successful CDMO PartnershipsIn an interview with European Biotechnology Magazine during J.P. Morgan Week in San Francisco, Dr. Jian Zhang, Acting CEO of BioDlink, explains how a partnership-first approach and deep ADC expertise … more ➔
RegulatorySFDA vs EMA: What Biotech Leaders need to KnowAs the regulatory strategy becomes a boardroom-level concern for biotech executives pursuing global expansion, knowing how the Saudi Food and Drug Authority (SFDA) and the European Medicines Agency (EMA) … more ➔
Pharmahungary GroupDrug DiscoverymiRNA discovery & development platformPharmahungary Group (PH) developed miRNAtarget, a miRNA discovery software tool based on miRNA-mRNA molecular networks. PH holds patent families on 4 cardio-protective microRNAs families (protectomiRs) … more ➔
Merck KGaA, Darmstadt GermanyPegylated TherapiesSelecting a CDMO for Custom Activated PEGsThis article examines the critical success factors for PEGylated therapies and the decision-making process for when a custom PEG may be warranted rather than an off-the-shelf solution. The essential … more ➔
Oncology ResearchTiny Models, Big ImpactOrganoids are reshaping cancer R&D by providing more accurate, patient-relevant models than classical methods. By bridging the gap between preclinical and early clinical stages, they enable patient-centric … more ➔
3PBiovian
BioDlink
Pharmahungary Group
Merck KGaA, Darmstadt Germany